The IoT security technology provider had raised $48m in funding from investors including Qualcomm and Čez pre-acquisition.

The Qiagen-founded precision cancer technology provider agreed to an acquisition by Invitae sized at at least $325m in cash and shares currently valued at about $820m.

Vcanbio scored an exit as the precision cancer treatment and diagnostics developer went public in an upsized offering priced well above its range.

Novartis is the second largest investor in the gene therapy developer, which has filed to go public less than a year after closing a $150m round.

The Fosun-backed smart apparel technology provider has filed to raise just over $50m on the Shenzhen Stock Exchange’s ChiNext market.

Samsung Catalyst Fund, BMW i Ventures and NavInfo all exited street-level image repository Mapillary in an acquisition by Facebook.

The Novartis and Eli Lilly-backed cancer and haematologic disease drug developer will go public today having expanded the size of its offering.

The targeted oncology drug developer, which counts Bristol Myers Squibb and Celgene as investors, is floating above its range in an upsized offering.

Rabies and meningities vaccine producer Kanghua Biological, which counts Aokang and Tigermed as investors, has floated in its home country of China.

New World Development and China Mobile Games and Entertainment will have the chance to exit the Asia-based gay dating app developer.